143 related articles for article (PubMed ID: 9863926)
21. Mucin-like carcinoma associated antigen (MCA) at presentation with breast cancer.
Horgan PG; Byrne J; O'Donoghue J; Mooney E; Grimes H; Given HF
Ir J Med Sci; 1997; 166(4):215-6. PubMed ID: 9394068
[TBL] [Abstract][Full Text] [Related]
22. TPS in breast cancer--a comparative study with carcinoembryonic antigen and CA 15-3.
van Dalen A
Tumour Biol; 1992; 13(1-2):10-7. PubMed ID: 1589693
[TBL] [Abstract][Full Text] [Related]
23. Estimation of the usefulness of neoplastic markers TPS and CA 125 in diagnosis and monitoring of ovarian cancer.
Zygmunt A; Madry R; Markowska J; Fischer Z
Eur J Gynaecol Oncol; 1999; 20(4):298-301. PubMed ID: 10475127
[TBL] [Abstract][Full Text] [Related]
24. Serum MCA, CA 125 and CA 19.9 determination in primary breast cancer.
Yenisey C; Güner G
Biochem Soc Trans; 1996 May; 24(2):302S. PubMed ID: 8736960
[No Abstract] [Full Text] [Related]
25. [Clinical study of serum tissue polypeptide-specific antigen in breast cancer].
Zheng H; He BF; Luo RC; You CX; Mai GF; Lu HF
Di Yi Jun Yi Da Xue Xue Bao; 2003 Aug; 23(8):823-5. PubMed ID: 12919909
[TBL] [Abstract][Full Text] [Related]
26. Mucin-like carcinoma-associated antigen (MCA) in breast cancer: clinical experience at the National Cancer Institute of Milan.
Seregni E; Crippa F; Botti C; Bellotti MG; Bogni A; Pizzichetta M; Bombardieri E
Int J Biol Markers; 1993; 8(2):124-9. PubMed ID: 8366295
[TBL] [Abstract][Full Text] [Related]
27. CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer.
Devine PL; Duroux MA; Quin RJ; McGuckin MA; Joy GJ; Ward BG; Pollard CW
Breast Cancer Res Treat; 1995 Jun; 34(3):245-51. PubMed ID: 7579489
[TBL] [Abstract][Full Text] [Related]
28. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients.
Blijlevens NM; Oosterhuis WP; Oosten HR; Mulder NH
Anticancer Res; 1995; 15(6B):2711-6. PubMed ID: 8669851
[TBL] [Abstract][Full Text] [Related]
29. Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis.
Vizcarra E; Lluch A; Cibrián R; Jarque F; Alberola V; Belloch V; García-Conde J
Breast Cancer Res Treat; 1996; 37(3):209-16. PubMed ID: 8825132
[TBL] [Abstract][Full Text] [Related]
30. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
[TBL] [Abstract][Full Text] [Related]
31. CA 15-3, ceruloplasmin and tissue polypeptide specific antigen as a tumour marker panel in breast cancer.
Ozyilkan O; Baltali E; Kirazli S
East Afr Med J; 2000 Jun; 77(6):291-4. PubMed ID: 12858925
[TBL] [Abstract][Full Text] [Related]
32. MCA performance in preoperative breast cancer patients.
Donadeo A; Micelli G; Quaranta M; Atlante A; Schittulli F
Anticancer Res; 1995; 15(2):527-9. PubMed ID: 7763034
[TBL] [Abstract][Full Text] [Related]
33. [Circulating proteinic biomarkers and breast cancer].
Mathelin C; Koehl C; Rio MC
Gynecol Obstet Fertil; 2006; 34(7-8):638-46. PubMed ID: 16876456
[TBL] [Abstract][Full Text] [Related]
34. New mucin-like cancer-associated antigens (CA M 26, CA M 29 and CA 549) and a new proliferation marker (TPS) in patients with primary or advanced breast cancer.
Locker GJ; Mader RM; Braun J; Sieder AE; Marosi C; Rainer H; Jakesz R; Steger GG
Oncology; 1995; 52(2):140-4. PubMed ID: 7854774
[TBL] [Abstract][Full Text] [Related]
35. Comparison of tissue polypeptide antigen (TPA) with cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in follow-up of breast cancer.
Findeisen R; Albrecht S; Richter B; Deutschmann K; Distler W
Clin Chem Lab Med; 1998 Nov; 36(11):841-6. PubMed ID: 9877089
[TBL] [Abstract][Full Text] [Related]
36. Clinical evaluation of potential usefulness of CEA, CA 15-3, and MCA in follow-up of breast cancer patients.
Jezersek B; Cervek J; Rudolf Z; Novaković S
Cancer Lett; 1996 Dec; 110(1-2):137-44. PubMed ID: 9018092
[TBL] [Abstract][Full Text] [Related]
37. TPA and CA 15.3 measurements for breast cancer monitoring in a routine setting.
Bonfrer JM; Korse CM
Int J Biol Markers; 1999; 14(1):40-4. PubMed ID: 10367249
[TBL] [Abstract][Full Text] [Related]
38. Use of serum tumor markers for the diagnosis and follow-up of breast cancer.
Barrenetxea G; Schneider J; Llorente MF
Oncology; 1998; 55(5):447-9. PubMed ID: 9732223
[No Abstract] [Full Text] [Related]
39. [Clinical importance of determination of tumor markers during follow-up in breast carcinoma].
Fínek J; Holubec L; Topolcan O; Pikner R; Sůvová B; Treska V
Cas Lek Cesk; 2004; 143(3):174-7. PubMed ID: 15134036
[TBL] [Abstract][Full Text] [Related]
40. Is tissue polypeptide antigen still a useful tumor marker in breast carcinoma? Comparison with CA15.3 and MCA.
Gion M; Mione R; Gatti C; Dittadi R; Leon A; Nascimben O; Pizzorno B; Bruscagnin G
Tumori; 1990 Aug; 76(4):360-4. PubMed ID: 2399565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
